Study of REGN1193 in Patients With Type 2 Diabetes Mellitus

NCT02284425 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: REGN1193
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals